BI Bets On Expanding Jardiance As Diabetes Drug Sales Soar

 
• By Kevin Grogan

The German major believes its drug will remain the biggest-selling SGLT-2 inhibitor boosted by expanded heart and renal disease approvals.

Boehringer Ingelheim ARPC
BI board reviews a strong 2018 performance • Source: Boehringer Ingelheim

More from Business

More from Scrip